CDCP1 Antibody-Drug Conjugates for Targeted Cancer Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective anti-CDCP1 antibodies and antibody drug conjugates (ADCs) for the treatment of cancer, as existing therapies are not sufficiently targeted and can have high toxicity.
Innovation Solution
Development of anti-CDCP1 antibodies and ADCs that bind specifically to CDCP1 with high affinity and can be internalized, inducing cell death in CDCP1-expressing cells, with various drug conjugates including anti-apoptotic agents, mitotic inhibitors, and other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies are used to treat cancer, then cancer cells can be killed, but toxicity is high and non-specific
Solution Approach 1:
The patent uses antibodies as intermediary molecules that specifically bind to CDCP1 antigen on cancer cells, delivering cytotoxic payloads selectively to tumor cells while sparing healthy tissues. This mediator approach resolves the contradiction by enabling targeted delivery of potent therapeutic agents without systemic toxicity.
Solution Approach 2:
The invention extracts the cytotoxic function from conventional chemotherapies and separates it from non-specific distribution. By conjugating cytotoxic agents to CDCP1-specific antibodies, the therapeutic effect is extracted and delivered only to CDCP1-positive cancer cells, eliminating the harmful non-specific toxicity of traditional chemotherapy.
2Object-affected harmful factors
If existing antibody therapies are developed, then targeted treatment is achieved, but sufficient efficacy against CDCP1-expressing cancers is not reached
Solution Approach 1:
The patent creates composite antibody-drug conjugates combining CDCP1-specific antibody moieties with potent cytotoxic payloads including auristatins, maytansinoids, and calicheamicin. These composite structures integrate the targeting capability of antibodies with the potent cell-killing activity of cytotoxic agents, achieving both reduced toxicity and enhanced effectiveness.
Solution Approach 2:
The invention optimizes multiple parameters including antibody affinity for CDCP1, drug-to-antibody ratio (DAR), linker stability and cleavage characteristics, and payload potency. By systematically adjusting these parameters, the conjugates achieve optimal balance between targeted delivery efficiency and cytotoxic effectiveness, resolving the contradiction between safety and efficacy.
3Adaptability or versatility
If non-specific chemotherapies are used, then broad cancer coverage is achieved, but targeting precision is low
Solution Approach 1:
The patent develops CDCP1-targeted ADCs that can treat multiple CDCP1-expressing cancer types including breast, lung, ovarian, and pancreatic cancers. The universal CDCP1 antigen target enables broad applicability across different cancer types while maintaining high targeting precision through antibody-specific binding, resolving the contradiction between versatility and precision.
Data Source
AI summary
This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.